Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

RxmiRcanceR

Financiado

Tumor suppressive microRNAs for cancer therapy

The challenge for cancer therapy involves hampering the mechanisms by which the normal gene expression machinery is taken over to allow the aberrant appearance of cancer driving genes. I propose exploiting the therapeutic potentia... ver más

31/08/2024

THE HEBREW UNIVERS...

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

THE HEBREW UNIVERSITY OF JERUSALEM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-08-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2017-ADG: ERC Advanced Grant

I+D

Cerrada hace 7 años

0% 100% 100%

2 Participantes

THE HEBREW UNIVERSITY OF JER...

2.84M€ | Lider

TIRME

1.48M€ | Participante

Proyectos interesantes

BFU2014-61881-EXP PERFILES DE EXPRESION DE LOS MICRORNAS CIRCULANTES EN LA HEM... 54K€ Cerrado

SAF2013-41027-R IDENTIFICACION DE NUEVAS ALTERACIONES MOLECULARES ASOCIADAS... 266K€ Cerrado

EVOLVE Isolation and Analysis of Extracellular Vesicles using Optof... 157K€ Cerrado

RTI2018-102046-B-I00 EXPLOTANDO EL MICROPROTEOMA PARA ENCONTRAR NUEVAS DIANAS MOL... 182K€ Cerrado

SAF2010-20832 CARACTERIZACION GENETICA DE LAS CANCER-STEM-CELLS (CSC) EN T... 36K€ Cerrado

BFU2009-09074 IDENTIFICACION DE MECANISMOS CAUSANTES DE CANCER Y METASTASI... 593K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 72 meses Fecha Inicio: 2018-08-24
Fecha Fin: 2024-08-31

Líder del proyecto

THE HEBREW UNIVERSITY OF JERUSALEM

TRL 4-5

Presupuesto del proyecto 3M€

Descripción del proyecto The challenge for cancer therapy involves hampering the mechanisms by which the normal gene expression machinery is taken over to allow the aberrant appearance of cancer driving genes. I propose exploiting the therapeutic potential of a special class of tumor microRNAs (miRs) that function as natural post-transcriptional tumor suppressive regulators of many genes in key pathways. These anti-cancer effectors represent an inherent organismal property that I propose to augment and thereby translate into a form of systemic anti-cancer therapy. First, focusing on hepatocellular carcinoma (HCC), I shall perform high throughput screening to identify preferred HCC tumor suppressive miRs. Second, I shall search for small molecules capable of elevating the level of those relevant miRs in tumor cells and tissues. Increasing miR expression will potentially also enhance their secretion into the circulation in exosomes thereby suppressing gene expression at remote tissue sites as well. Third, I shall test the potential of these miRs to better target and inhibit the growth of tumor cells both, in culture and in vivo. This unprecedented conceptual strategy should stimulate the organism’s self-healing potential by enhancing inherent anti-tumor mechanisms. This project is built on robust preliminary findings that show promiscuous anti-cancer effects and predictably fewer side effects due to its completely host-based nature, with the administered miR inducer being the only foreign element. Additionally, due to the fact that each miR simultaneously targets a number of molecular pathways as well as multiple steps within a given pathway, it could help to overcome the major problem of cancer therapy – resistance. This strategy of harnessing these efficient and robust miRs and exosomes for delivery of anti-cancer therapeutics may overcome the high-risk challenge involved and enable high gain value.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores